Cargando…
Reporting of Immune Checkpoint Inhibitor Therapy–Associated Diabetes, 2015–2019
Autores principales: | Liu, Jiaqing, Zhou, Huaqiang, Zhang, Yaxiong, Fang, Wenfeng, Yang, Yunpeng, Huang, Yan, Zhang, Li |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Diabetes Association
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305010/ https://www.ncbi.nlm.nih.gov/pubmed/32393586 http://dx.doi.org/10.2337/dc20-0459 |
Ejemplares similares
-
PBRM1 mutation and preliminary response to immune checkpoint blockade treatment in non-small cell lung cancer
por: Zhou, Huaqiang, et al.
Publicado: (2020) -
Immune-related pneumonitis associated with immune checkpoint inhibitors in lung cancer: a network meta-analysis
por: Chen, Xinru, et al.
Publicado: (2020) -
MDM2/4 amplification predicts poor response to immune checkpoint inhibitors: a pan-cancer analysis
por: Fang, Wenfeng, et al.
Publicado: (2020) -
Periprocedural Euglycemic Diabetic Ketoacidosis Associated With Sodium–Glucose Cotransporter 2 Inhibitor Therapy During Colonoscopy
por: Meyer, Emily J., et al.
Publicado: (2020) -
Increased Reporting of Immune Checkpoint Inhibitor–Associated Diabetes
por: Wright, Jordan J., et al.
Publicado: (2018)